TheEdgeResearch
Home / Stocks / RNLX

Renalytix Plc (RNLX)

NASDAQ Healthcare Medical - Healthcare Information Services
$0.21 ▲ +5.66%
Market Cap
$22.5M
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Beta
2.10
52-Wk Range
0.176-2.4
CEO
James R. McCullough
Country
US
Currency
USD

Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in…

Open full interactive analysis & DCF →